Peter Marks’ Departure From FDA Rattles Biopharma Industry

XBI Reaches A New 2025 Low

 
• By Mandy Jackson
  
FDA review of vaccines and cell and gene therapies could be held up under new CBER leadership (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Scrip